Technical Analysis for APLS - Apellis Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New Downtrend | Bearish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Doji - Bullish? | Reversal | 0.00% | |
| BB Squeeze + Lower Band Touch | Range Contraction | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | -1.43% | |
| NR7 | Range Contraction | -1.43% | |
| Hammer Candlestick | Bullish | -2.92% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 12 hours ago |
| Lower Bollinger Band Support | about 12 hours ago |
| Fell Below Lower Bollinger Band | about 14 hours ago |
| Fell Below Previous Day's Low | about 14 hours ago |
| Down 2 % | about 14 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/02/2023
Apellis Pharmaceuticals, Inc. Description
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company's lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Organ Systems Eye Inflammatory Diseases Macular Degeneration Pulmonary Disease Chronic Obstructive Pulmonary Disease Hemoglobin Autoimmune And Inflammatory Disease Complement System Acquired Hemolytic Anemia Hemoglobinuria Paroxysmal Nocturnal Hemoglobinuria Copd Intravitreal Administration
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 70.755 |
| 52 Week Low | 33.345 |
| Average Volume | 1,705,617 |
| 200-Day Moving Average | 55.17 |
| 50-Day Moving Average | 57.61 |
| 20-Day Moving Average | 64.21 |
| 10-Day Moving Average | 63.35 |
| Average True Range | 2.82 |
| RSI | 48.98 |
| ADX | 26.39 |
| +DI | 18.97 |
| -DI | 19.40 |
| Chandelier Exit (Long, 3 ATRs) | 62.30 |
| Chandelier Exit (Short, 3 ATRs) | 65.86 |
| Upper Bollinger Bands | 67.15 |
| Lower Bollinger Band | 61.27 |
| Percent B (%b) | -0.01 |
| BandWidth | 9.17 |
| MACD Line | 1.38 |
| MACD Signal Line | 2.10 |
| MACD Histogram | -0.7279 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 63.90 | ||||
| Resistance 3 (R3) | 63.96 | 63.12 | 63.45 | ||
| Resistance 2 (R2) | 63.12 | 62.44 | 63.09 | 63.30 | |
| Resistance 1 (R1) | 62.17 | 62.02 | 61.75 | 62.11 | 63.15 |
| Pivot Point | 61.33 | 61.33 | 61.13 | 61.30 | 61.33 |
| Support 1 (S1) | 60.38 | 60.65 | 59.96 | 60.32 | 59.27 |
| Support 2 (S2) | 59.54 | 60.23 | 59.51 | 59.12 | |
| Support 3 (S3) | 58.59 | 59.54 | 58.97 | ||
| Support 4 (S4) | 58.53 |
